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Abstract
The CRISPR-Cas9 system, naturally a defense mechanism in prokaryotes, has been repurposed as 
an RNA-guided DNA targeting platform. It has been widely used for genome editing and 
transcriptome modulation, and has shown great promise in correcting mutations in human genetic 
diseases. Off-target effects are a critical issue for all of these applications. Here we review the 
current status on the target specificity of the CRISPR-Cas9 system.
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The CRISPR-Cas9 System
The CRISPR-Cas system is widely found in bacterial and archaeal genomes as a defense 
mechanism against invading viruses and plasmids [1–6]. The type II CRISPR-Cas system 
from Streptococcus pyogenes relies on only one protein, the nuclease Cas9, and two 
noncoding RNAs, crRNA and tracrRNA, to target DNA [7]. These two noncoding RNAs 
can further be fused into one single guide RNA (sgRNA). The Cas9/sgRNA complex binds 
double-stranded DNA sequences that contain a sequence match to the first 17-20 nucleotides 
of the sgRNA if the target sequence is followed by a protospacer adjacent motif (PAM) 
(Figure 1). Once bound, two independent nuclease domains in Cas9 will each cleave one of 
the DNA strands 3 bases upstream of the PAM, leaving a blunt end DNA double stranded 
break (DSB). DSBs can be repaired mainly through either the nonhomologous end joining 
(NHEJ) pathway or homology-directed repair (HDR). NHEJ typically leads to short 
insertion/deletion (indels) near the cutting site, whereas HDR can be used to introduce 
specific sequences into the cutting site if exogenous template DNA is provided. This 
discovery paved the way for use of Cas9 as a genome-engineering tool in other species. In 
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this review, we focus on target specificity of the CRISPR-Cas9 system. We refer readers to 
other excellent reviews for further discussion of the CRISPR-Cas9 technology [8–11].
Applications of CRISPR-Cas9
Genome editing
The use of the CRISPR-Cas9 system as a tool to manipulate the genome was first 
demonstrated in 2013 in mammalian cells [12,13]. Both studies showed that expressing a 
codon-optimized Cas9 protein and a guide RNA leads to efficient cleavage and short indels 
of target loci, which could inactivate protein-coding genes by inducing frameshifts. Up to 
five genes have been mutated simultaneously in mouse and fish cells by delivering five 
guide RNAs [14,15]. Targeting two sites on the same chromosome can be used to create 
deletions and inversions of regions range from 100 bps to 1000000 bps [16,17]. Defined 
interchromosomal translocation such as those found in specific cancers can be created by 
targeting Cas9 to different chromosomes [18]. With exogenous template oligos, specific 
sequences such as HA-tag or GFP could be inserted into genes to label proteins [19,20], or 
to correct mutations in disease genes in human and mouse [21–23]. The system has also 
been adapted to many other species, including monkey, pig, rat, zebrafish, worm, yeast, and 
several plants [9].
Transcriptome modulation
Mutating the two nuclease domains of Cas9 generates the catalytically inactive Cas9 
(dCas9), or nuclease-null Cas9, which can bind DNA without introducing cleavage or 
mutation [7]. When targeted to promoters, dCas9 binding alone can interfere with 
transcription initiation, likely by blocking binding of transcription factors or RNA 
polymerases. When targeted to the non-template strand within the gene body, dCas9 
complex blocks RNA polymerase II transcription elongation [24–26]. Fusing dCas9 with 
transcription repressor domains such as the Krueppel-associated box (KRAB) leads to 
stronger silencing of mammalian genes, a technology termed CRISPRi [24]. Activation of 
transcription is also possible by fusing dCas9 with activator domains such as VP64. 
However, several studies showed that multiple sgRNAs targeting the same promoter need to 
be used simultaneously to change target gene expression substantially [27–29]. The position 
of target sites with respective to transcription start site (TSS) affects the efficiency of 
silencing or activation, a subject that needs to be further investigated for optimal target 
design [30].
Genomic loci imaging and other applications
To enable site-specific labeling and imaging of endogenous loci in living cells, GFP has also 
been fused to dCas9 [31]. In this case, tens of sgRNAs are required to target the same locus 
such that individual loci show up as punctate dots, unless the target locus contains targetable 
tandem repeats. The fusion of dCas9 with other heterologous effector domains could enable 
many other applications. For example, one could fuse dCas9 with chromatin modifiers to 
change the epigenetic state of a locus. Other potential applications of the system have been 
previously reviewed extensively [8,9].
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Assessing Cas9 Target Specificity
The original characterization of the Cas9/sgRNA system showed that not every position in 
the guide RNA needs to match the target DNA, suggesting the existence of off-target sites 
[7]. Concerns about off-target effects depend on the purpose of the targeting. As discussed 
above and below, Cas9/sgRNA binding at a site does not necessarily lead to DNA cutting or 
mutation, and binding or cutting may not have any functional consequence either, especially 
when the off-target sites are outside of genes or regulatory elements. The off-target effects 
of Cas9 cutting/mutation have been studied extensively but sensitive and unbiased genome-
wide characterization is still missing. Below we review existing approaches that have been 
or can be used to study Cas9 target specificity.
Assay of predicted off-targets
Typically a list of potential off-target sites are predicted based on sequence homology to the 
on-target, or using more sophisticated tools that incorporate various rules previously 
described in literature (see section “Tools for target design and off-target prediction”). Two 
types of assays are commonly used to detect and quantify indels formed at those selected 
sites: mismatch-detection nuclease assay and next generation sequencing (NGS). In the 
mismatch-detection nuclease assay, genomic DNA from cells treated with Cas9 and sgRNA 
is PCR amplified, denatured and rehybridized to form hetero-duplex DNA, containing one 
wildtype strand and one strand with indels. Mismatches can be recognized and cleaved by 
mismatch detection nucleases, such as Surveyor nuclease [32] or T7 endonuclease I [33], 
enabling quantitation of the products by electrophoresis. It is challenging to use this assay to 
detect loci with less than 1% indels and this assay is difficult to scale-up. Alternatively, the 
PCR product can also be sequenced directly using NGS platform. The fraction of reads with 
indels is quantified after mapping to the genome or directly to the amplicon. When 
combined with proper controls and statistical models, NGS based approaches are more 
accurate and sensitive than nuclease based assays.
Systematic mutagenesis
To characterize Cas9/sgRNA specificity, several groups performed systematic mutagenic 
analysis of the sgRNA or target DNA to evaluate the importance of the position, identity, 
and number of mismatches in the RNA/DNA duplex [12,34,35]. These studies revealed a 
very complicated picture of Cas9 specificity [36]. However, it is unclear whether the 
observed variation truly reflects specificity requirement, or is confounded by unintended 
changes caused by the mutations introduced in the sgRNA or target DNA. For example, 
mutations in the sgRNA could change the sgRNA abundance dramatically, which would 
alter the targeting efficiency [37]. Also mutations in DNA might create or disrupt binding 
sites for endogenous proteins that interfere with Cas9 binding. The number of variants 
evaluated is also limited in these studies. Finally, each study typically examines less than 
four target sites, leaving questions whether the observations can be generalized.
In vitro cleavage site selection
A more comprehensive way to study Cas9 cutting specificity is in vitro selection. In this 
assay a large pool of partially randomized targets are synthesized and cleaved by Cas9 or 
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other nucleases in vitro [38–40]. The cleavage leaves a 5′ phosphate group in the DNA, 
which can then be ligated to an adaptor and selectively amplified using PCR. The 
advantages of this approach are that the sequence space explored by the target library can be 
very large (1012 molecules, even larger than all possible sites in any genome), and that target 
specificity can be evaluated independently of genome or species used and is not affected by 
chromatin structure that is usually cell-type specific. However these advantages also impose 
potential limitations of this assay. Although the sequence space of the library can be huge, 
most substrates contain on average only 4-5 mismatches to the on-target [38]. Given that 
efficient cleavage with 7 mismatches has been observed [7], such an assay could still miss a 
significant fraction of genomic off-targets. For example, when the in vitro cleavage site 
selection approach was applied to another type of nuclease, the Zinc Finger Nuclease (ZFN), 
only one of the four off-targets identified by an in vivo assay was detected [40–42]. 
Alternatively, instead of using partially randomized synthetic DNA library, one could 
perform the same assay with genomic DNA to detect possible genomic off-targets.
It has also been reported that compared to in vivo conditions, Cas9 cutting is more 
promiscuous in vitro [43], i.e. off-targets are cleaved at much higher frequency in vitro than 
in vivo. This can be potentially explained by chromatin blockage of accessibility of the off-
target sites in vivo [37,44,45]. Therefore a potential solution is to perform in vitro selection 
assay using native or fixed chromatin prepared from cells. However, the higher rate of off-
target cutting could also be due to higher effective concentrations of Cas9/sgRNA used in 
vitro. A titration series of Cas9/sgRNA concentration is needed to assess the in vivo 
relevance of off-target sites identified by in vitro approaches.
DSB capture and sequencing
Cas9 and other DNA endonucleases typically induce DSBs, and several assays have been 
developed to capture DSBs induced in cells [41,46,47], although none of them have been 
applied to the Cas9 system. Gabriel et al. transformed human cells with integrase-defective 
lentiviral vectors (IDLVs), which are incorporated into DSBs via NHEJ pathway, thus 
tagging those transient cutting events [41]. This approach uncovered four in vivo off-target 
cleavage sites for a ZFN targeting the CCR5 locus. In another in situ assay called BLESS 
[47], cells are fixed first and then chromatin is purified and ligated with biotinylated DNA 
linkers. Both approaches could in principle be applied to Cas9 treated cells to uncover 
genome-wide cutting sites. Compared to in vitro cleavage site selection approaches, DSB 
capture approaches are physiologically more relevant, but can be less efficient since most 
DSBs exist very transiently, and the capture can be biased since both in vivo IDLV labeling 
and in situ linker ligation can be affected by local chromatin and sequence composition near 
the cutting site. Thus certain DSBs induced by the nuclease will not be tagged. For instance, 
of the 36 ZFN off-target sites identified by in vitro selection approach, only one is identified 
by the IDLV-based DSB capture [42]. In addition, DSB capture approaches may identify 
large number of false positive sites, since DSBs can be generated by endogenous cellular 
process independent of Cas9 cutting, or during the library preparation process. Proper 
controls, such as cells treated with no Cas9 or no sgRNA can be used to filter false positives.
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Whole genome sequencing
Compared to assays described above, whole genome sequencing (WGS) would be a less 
biased assessment of off-target mutations caused by Cas9, although it will miss off-target 
sites that are bound without cutting, or are cut but then always perfectly repaired. In addition 
to small indels, WGS can also detect Cas9 induced structural changes, such as inversions 
[16]. So far relatively high coverage (30-60×) of WGS has been performed in single clones 
of Cas9 treated cells in a variety of species, including worm [48], Arabidopsis [49], rice 
[50], and human pluripotent stem cells [51,52]. Interestingly, although a number of 
mutations were identified in Cas9 treated clones, none were found to be near sites with 
sequences similar to the target, indicating Cas9 induced off-target mutations are rare and it is 
possible to obtain clones without off-target mutations. However, due to the high cost, only a 
few clones have been sequenced for each target, which would miss most low-frequency off-
target events. For example, if there was a single possible off-target site per genome mutated 
at a 40% frequency relative to the on-target site, this could have escaped detection in these 
experiments. However, if there were 10 possible off-target sites per genome mutated at a 
40% frequency, then at least one of these sites should have been detected. Therefore, WGS 
is ideal for screening individual clones for off-targets, but at the moment, it is not practical 
for systematic study of a large number of guide RNAs to determine the rules governing Cas9 
specificity.
Whole genome binding
Chromatin immunoprecipitation (ChIP) is a widely used technique for assaying genome-
wide binding of proteins on DNA in vivo [53]. Briefly, live cells are crosslinked, lysed and 
chromatin fragmented and then immunoprecipitated to pull down DNA bound by a specific 
protein. The DNA is then purified and assayed by microarray or NGS. Compared to other 
readouts, such as indels that are downstream of the repair pathway, or gene expression 
changes, which are also affected by relative position of binding to the transcription start site, 
ChIP provides direct evidence for Cas9 binding on the genome. We and other groups 
recently generated the first maps of dCas9 binding on mammalian genomes [37,44,45]; all 
three studies revealed a large number of binding sites, for example up to six thousand in 
mouse embryonic stem cells, as well as substantial variation (200 fold) in the number of off-
target sites between sgRNAs [37]. Specificity was not altered by fusion to an effector 
domain, as dCas9-KRAB had a similar binding profile to dCas9 alone [45]. Surprisingly, 
two of these studies observed little cutting/mutation at most off-targets tested, while one 
study observed significant cleavage at 30 out of 57 selected off-target sites, albeit at a 
substantially lower rate than on-target cleavage [44]. We further observed little to none of 
the off-target gene expression change which would presumably result from strong dCas9 
binding at many off-target sites (Wu et al., unpublished data). It is possible that most of the 
off-targets detected by ChIP are weak and transient interactions stabilized by crosslinking. 
Native ChIP without crosslinking may help to clarify this question. The other limitation of 
ChIP approach is that it is inherently biased towards open chromatin and highly transcribed 
genes [54]. There could be other biases that remain to be discovered. For example, we failed 
to detect binding at previously validated off-target sites using an NAG PAM [37]. It is also 
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unclear whether the two mutations introduced in dCas9 alter the target binding specificity as 
compared to wild type active Cas9.
Transcriptome profiling
For application in transcription modulation, transcriptome profiling by either microarray or 
RNA-seq is the ultimate read out for assessing off-target effects. In all published cases 
[25,27,55], no significant off-target gene expression changes were observed, which again is 
unexpected given the large number of off-target binding sites reported in ChIP-based 
studies, and that off-target binding is enriched in accessible active regulatory elements [37]. 
It also remains to be seen whether marginally affected genes are enriched for off-target 
binding sites.
Determinants of Cas9/sgRNA Specificity
Despite potential bias, the assays and studies described above revealed many factors that 
could affect Cas9/sgRNA targeting specificity (Figure 2), and these can be broadly classified 
into two categories. First, the intrinsic specificity encoded in the Cas9 protein, which likely 
determines the relative importance of each position in the sgRNA for target recognition, 
which may vary for different sgRNA sequences. Secondly, the specificity also depends on 
the relative abundance of effective Cas9/sgRNA complex with respect to effective target 
concentration. Below we discuss factors that could affect target specificity.
PAM
The protospacer-adjacent motif (PAM) is strictly required to be immediately next to the 3′ 
end of the target sequence. The PAM is recognized by an individual domain in the Cas9 
protein [56], and the PAM sequence varies across bacteria species [57,58]. Presumably 
species with longer PAM, having less targetable sites in the genome, will have 
correspondingly fewer off-targets, although this has not been directly tested. For the widely 
used Cas9 from Streptococcus pyogenes, the PAM is typically NGG, where the first position 
shows no nucleotide bias. Recent data suggested that PAM binding is required for both 
opening the DNA and target cleavage [56,59]. Both in vitro [38] and in vivo [29,34,60] 
cleavage data suggested that NAG is also tolerated to some extent, especially when Cas9/
sgRNA is in excess to target DNA. In addition, other variants that contain at least one of the 
two G's at position 2 and 3, i.e. NNG or NGN, could lead to some cleavage activity in vitro 
under Cas9 excess conditions [38]. Interestingly recent genome-wide ChIP-seq data revealed 
no significant Cas9 binding at NAG targets [37,44,45], including previously validated off-
target NAG cleavage sites, suggesting ChIP may not be able to detect off-target sites with 
certain PAMs.
Seed
In the original characterization of CRISPR-Cas9 [7], mismatches in the first 7 positions 
(PAM-distal) of the guide RNA are well tolerated in terms of cleavage of a plasmid in vitro. 
Further studies in bacteria and mammalian cells showed that mismatches in the 10-12 base 
pairs in the PAM-proximal region usually lead to decrease or even complete abolishment of 
target cleavage activity. Another study reported that Cas9 can even cleave DNA sequences 
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that contain insertions or deletions relative to the guide RNA; however many of these sites 
could be alternatively aligned to contain only mismatches to the guide [61]. Thus, the PAM-
proximal 10-12 bases have been defined as the seed region for Cas9 cutting activity [12,62]. 
However, a relatively comprehensive in vitro cleavage and selection approach revealed no 
clearly defined seed region for four guide RNAs, although the results confirmed that 
mismatches near the PAM region are less tolerated [38]. In contrast, in two genome-wide 
binding datasets, one out of two [45] and three of the four [37] sgRNAs tested showed a 
clearly defined seed region, only the first 5 nucleotides next to PAM. A third genome-wide 
binding dataset detected no obvious seed for twelve sgRNAs tested, although PAM proximal 
bases tended to be more preserved than PAM distal bases in binding sites [44]. However, the 
same data, when analyzed with our pipeline, revealed the 5-nucleotide seed region for three 
out of twelve sgRNAs (Wu et al., unpublished data); this is likely due to differences in 
selecting the best match to the guide region near binding sites, e.g. accepting matches with 
alternative PAMs. Hundreds of binding sites detected by ChIP in vivo contain only seed 
match with mismatches at all the other 15 positions in the guide RNA [37]. We also showed 
that seed-only sites could be bound by Cas9/sgRNA complex in vitro using a gel shift assay. 
The variation in the length of the seed detected by different assays likely stems from 
different concentrations of factors and lengths of dwell times required for Cas9 binding and 
cleavage.
Cas9/sgRNA abundance
Cas9 cutting becomes less specific at higher effective concentrations of Cas9/sgRNA 
complexes. For example, in vitro, when excessive amounts of Cas9/sgRNA complex are 
present, mismatches in the guide matching region are more tolerated, and Cas9 can even cut 
at sites with mismatches in the PAM region [38]. Hsu et al. also showed that in vivo the 
specificity (ratio of indel frequency at target vs off-target) increases when decreasing 
amounts of Cas9 and sgRNA plasmids are transfected into cells [34]. Genome-wide, we 
have found that increasing Cas9 protein levels by 2.6 fold leads to a 2.6 fold increase in the 
number of off-target binding peaks in the genome. On the other hand, at a constant level of 
Cas9 protein, titrating the amount of sgRNA expression plasmid transfected, and thus the 
abundance of sgRNA, largely determines the number of off-target binding sites in the mouse 
genome [37].
Target or guide sequence
In addition to targeting Cas9 to a certain region in the genome, the sequence of the sgRNA 
alone appears to affect specificity [13,34,35,38]. For example, the tolerance of mismatches 
at each position varies dramatically between different sgRNAs, an observation that remains 
to be understood.
Possible mechanisms whereby a change in sgRNA sequence could affect Cas9 specificity 
include: 1) Changes that alter the effective concentration of sgRNA (by modulating 
transcription of the sgRNA, the stability of the sgRNA, or sgRNA loading into Cas9). For 
example, we found that two mutations in the seed region can increase U6 promoter 
transcribed sgRNA's abundance by at least 7 fold [37]. 2) Changes that alter the number of 
seed-matching sites in the genome, which can vary by 100-fold. 3) Changes that depend on 
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the local chromatin environment of the target DNA sequences (i.e. chromatin accessibility). 
4) Changes that might cause off-target effects by blocking the binding of trans-acting factors 
that may potentially affect Cas9 binding or reporter gene transcription. 5) Changes that alter 
the thermodynamic stability of the guide RNA-DNA duplex. It is likely that the observed 
effects of sgRNA sequence on specificity are the result of multiple mechanisms described 
above. Below we will discuss some of these effects in detail.
Accessibility of seed match genomic sites
In cells DNA is packed in chromatin and may have limited accessibility for Cas9 PAM 
recognition and target binding. DNase I hypersensitivity (DHS) is typically considered to be 
an indicator of chromatin accessibility. We have shown that DHS is a strong predictor of 
whether a 5-nucleotide seed followed by NGG (seed + NGG) site will be bound in vivo [37], 
and others have also observed a strong correlation between Cas9-bound sites and open 
chromatin [44,45]. In fact, the number of seed + NGG sites in DHS peaks (accessible seed + 
NGG sites) accurately predicts the number of ChIP peaks detected in vivo (R2= 0.92) [37]. 
Interestingly, designed target sites not in DHS peaks show significant ChIP enrichment over 
background, in our case comparable to that of target sites in open chromatin, suggesting that 
chromatin accessibility is not a requirement for binding to the on-target site [37,44]. This is 
consistent with previous studies showing that dCas9-VP64 fusion protein could be targeted 
to non-open chromatin regions to activate target gene transcription [55]. In sum, chromatin 
accessibility seems to be preferentially facilitating off-target binding.
The preferential enrichment of off-targets in accessible chromatin has implications for 
dCas9-based transcriptome modulation. In fact, we found that regulatory elements of active 
genes, such as promoters and enhancers, are significantly enriched for off-target binding 
since those elements are accessible when active. To what extent these off-target binding 
events lead to gene expression change remains to be addressed.
Abundance of seed match genomic sites
Given that the binding seed length is relatively short (5 to 12), each guide RNA potentially 
has thousands to hundreds of thousands of seed match sites in the mammalian genome that 
are followed by NGG [37]. However, due to mutational bias and other sequence bias in the 
genome, the occurrence of specific seed sequences could vary dramatically. For example, 
there are about 1 million AAGGA + NGG sites in the mouse genome, compared to less than 
10,000 CGTCG + NGG sites. Therefore it is important to consider abundance of seed sites 
when designing sgRNA targets for dCas9 based applications. We have shown that the 
number of accessible seed + NGG sites in the genome can very accurately predict the 
number of peaks detected by ChIP (R2= 0.92), although we only tested four guide RNAs 
[37].
Epigenetics
In addition to chromatin accessibility, we have also shown that for target sites with CpG 
dinucleotides, methylation status strongly correlates with ChIP signal [37]. Specifically, 
more methylation is associated with less binding, a correlation even stronger than DHS for 
the same set of sites. Consistent with the observation that CpG methylation is typically 
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associated with chromatin silencing, we observed a strong negative correlation between 
DHS and CpG methylation. However, the correlation between CpG methylation and Cas9 
binding remained strong even after subtracting the effect of DHS. Previously Hsu et al. 
showed that in vitro CpG methylation has no effects on Cas9 cutting of substrates with no 
mismatches to the guide RNA, and in vivo, Cas9 could mutate a promoter that is highly 
methylated, albeit with low indel frequency [34]. Taking this information together, we 
speculate that CpG methylation may represent chromatin accessibility not detected by DHS 
and like DHS, CpG methylation only affects binding at off-target sites. Similarly histone 
modifications may affect target site accessibility, although so far this has not been 
investigated.
Target sequence length
One might expect that if the guide region is longer than 20 nucleotides, a longer RNA-DNA 
duplex may be formed and thus the Cas9/sgRNA complex might have higher specificity. 
Ran et al. increased the length of the guide region to 30 nucleotides by extending the 5′ end 
of the sgRNA. Interestingly Northern blots detected that the extended 5′ end was trimmed in 
vivo [60], suggesting that Cas9 only protects about 20 nucleotides of the guide RNA and 
free sgRNA is largely unstable. On the other hand, it has been recently reported that when 
sgRNA is truncated to 17 or 18 nucleotides, the specificity increases dramatically [63]. The 
mechanism underlying this increased specificity is unclear. It was assumed the increased 
specificity is because the first 2-3 nucleotides are not necessary for on-target binding but 
instead stabilize off-target binding [63]. The other possibility is that shortened sgRNA may 
simply be less abundant or less efficiently loaded into Cas9.
sgRNA scaffold
In addition to the 5′ end, various modifications have been introduced to the scaffold region 
of the guide RNA, although their impact on target specificity is not well studied. Extension 
or truncation at the 3′ end can drastically change sgRNA expression levels [34], likely due to 
change in transcription or RNA stability, which in principle could affect specificity by 
tuning the effective concentration of Cas9/sgRNA complexes. Modifications have also been 
introduced to stabilize the sgRNA by flipping an A-U base pair at the beginning of the 
scaffold [31]. Increasing the length of a hairpin that is supposed to be bound by Cas9 also 
helps to increase the efficiencies for both imaging and transcription regulation, likely due to 
more efficient loading of sgRNA into Cas9. The effect of these modifications on the 
specificity of binding or cutting remains unclear, although it is reported that these 
modifications lead to higher signal to background ratio for imaging [31].
Strategies to Increase Specificity
Controlling Cas9/sgRNA abundance and duration
Typically Cas9 and sgRNA are expressed in cells by transient transfection of expressing 
plasmids. Titrating down the amount of plasmid DNA used in transfection increases 
specificity, although there is a trade-off for decreased efficiency at the on-target site. This is 
particularly an issue when the promoter is very strong, i.e. successfully transfected cells 
express a large amount of Cas9 and sgRNA leading to off-target effects. More recently, 
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sgRNA has been expressed by RNA Pol II transcription and processed from introns, 
microRNAs, ribozymes, and RNA-triplex-helix structures, providing more flexible control 
of the sgRNA abundance [64,65].
Alternative delivery methods have also been developed to increase specificity. Compared to 
plasmid transfection based delivery, direct delivery of recombinant Cas9 protein and in vitro 
transcribed sgRNA, either individually or as purified complex, reduces off-targets in cells 
[66,67]. This is likely due to the rapid degradation of the protein and RNA in cells, which 
would lower the effective concentration of the Cas9-sgRNA effector complex and its 
duration in cells.
Paired nickase
The Cas9 “nickase” generated by mutating only one nuclease domain can only cleave one 
strand of the target DNA, which creates a nick thought to be repaired efficiently in cells. 
When the nickase is targeted to two neighboring regions on opposite strands, the offset 
double nicking leads to a double stranded break with tails that are degraded and 
subsequently indels in the target region. The requirement of dual Cas9 targeting to a nearby 
region dramatically increases the specificity, since it is generally unlikely that two guide 
RNAs will also have nearby off-targets. The limitation of this strategy is that nicks induced 
by Cas9 could still lead to mutations in off target sites via unknown mechanisms 
[13,29,60,63].
dCas9-FokI dimerization
FokI nuclease only cuts DNA when dimerized [68]. Fusion of dCas9 to FokI monomers 
creates an RNA-guided nuclease that only cuts the DNA when two guide RNAs bind nearby 
regions with defined spacing and orientation, thus substantially reducing off-target cleavage 
[69,70]. It has been reported that RNA-guided FokI nuclease is at least four fold more 
specific than paired Cas9 nickase [69], likely due to FokI nuclease only functioning when 
dimerized whereas Cas9 nickase can cleave as a monomer [70]. Similar to paired nickases, 
the requirement of two nearby PAM sites with defined spacing and orientation reduces the 
frequency of target sites in the genome.
Tools for Target Design and Off-target Prediction
Several tools have been developed for designing sgRNA targets, with the primary 
consideration to avoid off-targets in the genome [34,71–80]. These tools typically consider 
an input sequence, a genomic region, or a gene and output potential target/guide sequences 
with predicted minimized off-target effects. Many of the tools also provide predicted off-
target sites for a given sgRNA. These tools vary in their scheme for scoring potential guides 
and off-targets. Some tools incorporate data from previous systematic mutagenic studies 
[34] or user-input penalties [72,77] to individually score off-targets based on location and 
number of mismatches to the guide. Other tools have binary criteria for off-targets, such as 
sites with less than a certain number of mismatches to the entire guide region [74,79,80], or 
to some defined PAM proximal or distal region [71,73,75,76,78]. Potential guides are 
generally ranked by a weighted sum of off-target scores, or by number of off-targets.
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Several tools consider factors beyond position and number of mismatches. Some tools [77] 
include the option to score off-targets with alternate PAMs based on the finding that Cas9 
cleaves these sites with lower efficiency [29,34,38,60]. In terms of the on-target site, various 
tools consider presence of SNPs and secondary structure [71] in the potential guide, which 
could impact targeting and loading of the sgRNA [81], genomic context of the guide (e.g. 
exons, transcripts, CpG islands), which could impact the intended purpose of the sgRNA 
[72,75], and GC content, which could impact effectiveness of the sgRNA [72,75,78,82].
Information from these tools is usually downloadable and sometimes viewable in an 
interactive format [34,75]. In addition, some tools provide support beyond finding potential 
guides, such as sequences of oligonucleotides for sgRNA construction [78–80] or primers 
for validation of cleavage at the target site [75,78]. Some tools also provide specialized 
modes for design of sgRNA with paired Cas9 nickases [34,72,73,78–80] or RNA-guided 
FokI nucleases [78–80].
Each of these tools has its advantages and disadvantages. Researchers seeking to design 
CRISPR-Cas9 targets in less well-studied organisms or alternative species of Cas9 will need 
to use tools that accept user-input genomes [71,73,74,77,78], are tailored for their organism 
[76], accept alternate PAM [73–75] or user-input PAM [77]. The desired purpose of the 
CRISPR-Cas9 guide is also an important factor to consider. For example, some tools focus 
on designing sgRNAs to target genes with high efficacy [75]. If off-target effects are more 
of a concern, it may be helpful to use a tool that scores predicted off-targets quantitatively 
[34,72,77]. The type of off-targets detected by each tool also varies; most tools only search 
for off-targets with few (typically three or less) PAM-proximal or total mismatches to the 
guide [71,75,76,79,80]. Considering what we have discussed in this review, especially for 
applications of dCas9, these may fail to detect many potential off-targets compared to tools 
that consider off-targets with more mismatches to the guide [34,72–74,77,78]. Since almost 
every tool has unique features, it may be useful to incorporate multiple tools during the 
design process. We refer readers to Supplementary Table for a more detailed comparison.
Overall, these tools could aid in designing sgRNA targets that have minimal sequence 
homology to other sites in the genome. However, many features that are important to 
sgRNA specificity, as we have discussed, remain to be implemented, such as impact of seed 
sequence on sgRNA abundance, seed abundance in the genome, and epigenetic features. 
These factors, as we have discussed, are currently thought to primarily affect binding, or 
dCas9 based applications.
Perspective
Despite intense study, the rules governing the specificity of Cas9/sgRNA targeting, 
especially target cutting and mutation remain elusive. At this stage, it is still challenging to 
predict genome-wide off-targets of Cas9 with any significant confidence. Although our 
genome-wide binding data set shows that the number of off-target peaks can be accurately 
predicted from the number of accessible seed + NGG sites, predicting binding at individual 
sites remains challenging [37]. This suggests that there could be other factors, such as 
higher-level chromatin structure, that further limit binding of Cas9.
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In addition, the relationship between Cas9 binding and functional consequences such as 
cleavage, mutation and transcription perturbation remains elusive. Several lines of evidences 
suggest that most Cas9 off-target binding events may be transient and have little functional 
impact. First, in two separate studies, only one of the 295 off-target binding sites [37] or one 
out of 473 off-target binding sites [45] tested showed evidence of mutations in cells 
expressing active Cas9 and corresponding sgRNAs. Secondly, transcriptome profiling 
revealed negligible off-target gene expression change [25,27,55]. Furthermore, theoretical 
calculation implies an exponential decay in activity from Cas9 binding to downstream 
effects such as gene expression change [29]. However, a direct comparison between 
genome-wide binding, cutting, and transcriptome change will be needed to support this 
claim.
The current rules of Cas9/sgRNA specificity are likely incomplete and biased. Most assays 
described here are biased, and may only detect a fraction of the off-target sites in cells and 
predict many false positives. Integration of multiple assays will likely lead to more 
comprehensive and more accurate identification of off-targets. For example, intersecting 
ChIP-detected Cas9 binding sites with whole-genome sequencing data will likely lead to 
authentic Cas9 target sites while removing Cas9-independent false positives, such as 
sequencing error or ChIP bias.
In addition to biased assays, the rules learned from each study are also likely biased by the 
small number of sgRNAs studied, given that the target specificity highly depends on the 
target sequence. Most of the assays described here are difficult to scale-up, such as ChIP, in 
vitro selection, and whole-genome sequencing. Further development of multiplexable 
unbiased assays, such as DSB capture with barcoded linkers, could facilitate the study of 
large number of sgRNAs at the same time.
The issue of off-targets is most critical in use of the Cas9 system to mutate specific genes. 
Here off-targets could generate spurious phenotypes and mistaken interpretations. This is 
particularly a concern when a large library of Cas9 vectors is screened with selective 
conditions for specific phenotypes. In this case a rare off-target mutation could be selected 
and the phenotype accredited to the on-target gene. The only really valid assay under these 
conditions is the deep sequencing of the total genome of the cloned mutated cell. However, 
this is much too expensive for most experiments and will only be done in particular cases. 
The principles summarized here about specificity of the Cas9 system hopefully will lead to 
experimental designs that optimize the probability of obtaining desired on-target mutants in 
the absence of unknown off-target changes.
Lastly, alternative Cas9 protein and guide RNA architecture may improve specificity. 
Several alternative Cas9 proteins from various bacteria have been studied and display very 
different PAM sequences [83]. Comprehensive characterization of the specificity, such as 
genome-wide binding and cutting, may identify novel Cas9 proteins with dramatically 
improved specificity. With an available crystal structure [56], it is also possible to design a 
new Cas9 protein with increased specificity via protein engineering and in vitro evolution.
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Figure 1. The CRISPR-Cas9 system
The sgRNA (purple) targets the Cas9 protein to genomic sites containing sequences 
complementary to the 5′ end of the sgRNA. The target DNA sequence needs to be followed 
by a proto-spacer adjacent motif (PAM), typically NGG. Cas9 is a DNA endonuclease with 
two active domains (red triangles) cleaving each of the two DNA strands three nucleotides 
upstream of the PAM. The five nucleotides upstream of the PAM are defined as the seed 
region for target recognition.
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Figure 2. Factors that impact Cas9 specificity
(Top) Before Cas9 is introduced to the system, specificity can be modified by altering the 
architecture of the single guide RNA (sgRNA) or the Cas9 protein itself. (Middle) At the 
DNA level, beyond the PAM requirement for binding, closed chromatin and methylated 
DNA negatively impact Cas9 binding, while increased abundance of Cas9/sgRNA 
complexes and guide sequences in the genome positively impact Cas9 binding. (Bottom) 
Although Cas9 can transiently bind DNA that is complementary to only a small seed 
sequence in the sgRNA, only sequences with extensive complementarity to the guide will be 
cleaved or direct activation or silencing of targeted genes.
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